Last reviewed · How we verify
CEND-1
At a glance
| Generic name | CEND-1 |
|---|---|
| Also known as | iRGD, LSTA1, certepetide, Certepetide |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (PHASE1, PHASE2)
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (PHASE2)
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (PHASE1, PHASE2)
- The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1, PHASE2)
- A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma (PHASE2)
- CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |